- CORRESPONDENCE
Manage risk of accidental gene editing of germline
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 568, 458 (2019)
doi: https://doi.org/10.1038/d41586-019-01284-6
Competing Interests
D.G.M. has been a scientific consultant and/or received honoraria or stock options from Biogen Idec, AMO Pharma, Charles River, Vertex Pharmaceuticals, Triplet Therapeutics, LoQus23, BridgeBio, Small Molecule RNA and Lion Therapeutics. He also had a research contract with AMO Pharma. He is also on the Scientific Advisory Board of the Myotonic Dystrophy Foundation, is a scientific adviser to the Myotonic Dystrophy Support Group and is a vice-president of Muscular Dystrophy UK.